Skip to content
OpenCapital
Get started

Bausch + Lomb BLCO Gain (Loss), Foreign Currency Transaction, before Tax

Gain (Loss), Foreign Currency Transaction, before Tax at other companies

Amneal Pharmaceuticals, Inc. logo
Amneal Pharmaceuticals, Inc.AMRX
——

Other financials

Income statement

See full
Revenue$1.2B+9.4%
Operating income$33.0M+140%
Net income-$71.0M+66.5%
EPS (diluted)-$0.20+66.7%

Balance sheet

See full
Cash & equivalents$279.0M+29.8%
Total debt$5.0B+4.3%
Total equity$6.4B+0.3%
Total assets$13.8B+2.6%

Cash flow

See full
Operating cash flow$32.0M+228%
CapEx$100.0M-9.1%
Free cash flow-$68.0M+49.6%

Valuation

See full
Market cap$5.43B+10.2%

Profitability

See full
Operating margin4.4%+2.9pp
Net margin-4.2%-1.3pp
FCF margin-3.4%0.0pp

Returns & leverage

See full
Return on equity-3.4%-0.9pp
Debt / equity0.8×0.0×
Current ratio1.5×0.0×

Where this comes from

Reported directly by Bausch + Lomb in its filing.

Tagged under the XBRL concept us-gaap:ForeignCurrencyTransactionGainLossBeforeTax.

The official record: Bausch + Lomb’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bausch + Lomb's gain (loss), foreign currency transaction, before tax.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Bausch + Lomb's gain (loss), foreign currency transaction, before tax?
Bausch + Lomb (BLCO) reported gain (loss), foreign currency transaction, before tax of -$3M in Q1 2026.
How has Bausch + Lomb's gain (loss), foreign currency transaction, before tax changed year-over-year?
Bausch + Lomb's gain (loss), foreign currency transaction, before tax increased by 50.0% year-over-year, from -$6M to -$3M.
What is the long-term trend for Bausch + Lomb's gain (loss), foreign currency transaction, before tax?
Over 3 years (2021 to 2025), Bausch + Lomb's gain (loss), foreign currency transaction, before tax has grown at a 10.9% compound annual growth rate (CAGR), from -$11M to -$15M.